GSA Capital Partners LLP Has $1.67 Million Stock Holdings in Cerus Co. (NASDAQ:CERS)

GSA Capital Partners LLP lessened its position in Cerus Co. (NASDAQ:CERS) by 34.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 959,978 shares of the biotechnology company’s stock after selling 505,044 shares during the quarter. GSA Capital Partners LLP owned approximately 0.52% of Cerus worth $1,670,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in Cerus by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 9,983,963 shares of the biotechnology company’s stock valued at $18,870,000 after buying an additional 113,292 shares during the last quarter. Silvercrest Asset Management Group LLC increased its position in shares of Cerus by 4.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 2,696,560 shares of the biotechnology company’s stock worth $5,096,000 after purchasing an additional 114,628 shares during the last quarter. Hood River Capital Management LLC increased its position in shares of Cerus by 390.4% during the 2nd quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock worth $2,587,000 after purchasing an additional 1,170,060 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Cerus by 6.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,257,571 shares of the biotechnology company’s stock worth $2,188,000 after purchasing an additional 71,007 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Cerus by 10.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 614,446 shares of the biotechnology company’s stock worth $1,081,000 after purchasing an additional 57,073 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analysts Set New Price Targets

Separately, Stifel Nicolaus lowered their price target on Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th.

Insider Transactions at Cerus

In other news, CFO Kevin Dennis Green sold 28,385 shares of Cerus stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the transaction, the chief financial officer now directly owns 590,365 shares in the company, valued at approximately $1,286,995.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.40% of the stock is currently owned by corporate insiders.

Cerus Stock Performance

Shares of NASDAQ CERS opened at $1.89 on Wednesday. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.59. The stock has a 50 day moving average of $1.80 and a 200-day moving average of $1.92. The company has a market capitalization of $350.99 million, a P/E ratio of -17.18 and a beta of 1.20.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.